Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAS060 is a topical, non-steroidal formulation developed for the treatment of mild-to-moderate atopic dermatitis. It is a variant of the MAS063DP (Atopiclair) formulation, containing lower concentrations of key active ingredients including glycyrrhetinic acid, telmesteine, and *Vitis vinifera* extract, and is formulated without preservatives. MAS060 functions as a barrier-repair cream intended to restore skin integrity and provide anti-inflammatory and antioxidant effects. In clinical studies involving pediatric patients, MAS060 demonstrated significantly lower efficacy compared to the standard MAS063DP formulation and did not show a statistically significant difference from the vehicle control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MAS060.